Clinical trial
Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00014170 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00014170 |
|---|---|
| Title | Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme |
| Official title | Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma |
| Intervention type | Drug, Other, Procedure |
| Interventions | gefitinib, pharmacological study, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment |
| Enrollment | 92 |
| Start date | Mar 1, 2001 |
| Primary completion | Jul 1, 2003 |
| First posted | Jun 10, 2003 |
| Last update posted | Jul 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: